BP Retatrutide 64Mg Pen

BodyPharm Retatrutide 64mg Pen is one of the strongest next-generation GLP-1 / GIP / Glucagon triple-agonist weight-loss peptides (GLP-3). Designed for fast fat burning, extreme appetite suppression, metabolic acceleration, and consistent weekly results, this powerful multi-pathway pen is ideal for advanced users or those who have plateaued on Semaglutide or Tirzepatide.

Perfect for clients needing stronger, more aggressive weight-loss support.

 

 How It Works:

Retatrutide supports rapid and sustained fat loss by activating three pathways at once:
✅ GLP-1 → powerful appetite suppression
✅ GIP → enhanced insulin sensitivity & fat regulation
✅ Glucagon receptor → increased metabolic rate & fat burning

Combined, these create:
• Strong reduction in cravings
• Faster metabolic output
• Better appetite control
• Significant weekly fat loss
• Improved long-term weight stability

Each pen contains 64mg Retatrutide with a preset click-dose dial for accuracy.

—

How to Use It (Weekly Dosing Schedule):

Based on the BodyPharm dosing printed on your box:

Weeks 1–4:
• 2mg once per week
(Intro phase to reduce nausea)

Weeks 4–8:
• 4mg once per week
(Therapeutic fat-loss phase)

Week 8 and Up – Maintenance or Accelerated Phase:
• 8mg once per week

❌ Do NOT exceed 8mg weekly unless medically supervised.

Important Notes:
• This is a pre-filled multi-dose pen with click-based dosing
• Inject subcutaneously (abdomen, thigh, or upper arm)
• Rotate injection sites weekly
• Drink enough water to avoid dehydration
• Combine with high-protein meals for best results
• Not suitable for pregnant or breastfeeding women

Always consult with a healthcare provider for personalized adjustment.

Features & Benefits:

• 64mg high-strength BodyPharm Retatrutide
• Triple pathway activation: GLP-1 + GIP + Glucagon
• Strong appetite suppression & craving control
• Rapid weekly fat loss
• Increased metabolism & calorie burn
• Simple weekly dosing
• GMP-certified & pharmaceutical-grade quality
• Ideal for advanced weight-loss users